LGA
NAGE

Lebenthal Global Advisors’s Niagen Bioscience NAGE Stock Holding History

Lebenthal Global Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-934
Closed -$4K – 566
2020
Q4 		$4K Buy
+934
New +$4.55K ﹤0.01% 512

Other funds holding NAGE

YRHAM
Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Lebenthal Global Advisors's NAGE Position: Q1 2021 in Review

Lebenthal Global Advisors sold out of Niagen Bioscience (NAGE) in Q1 2021, closing a stake of 934 shares — an estimated $4K sold.

Lebenthal Global Advisors first reported a position in NAGE in Q4 2020 and held it in 1 quarter. The position peaked at $4K in Q4 2020. 96 funds tracked by Wall St. Rank hold NAGE as of Q1 2021.

  • Lebenthal Global Advisors reported no remaining Niagen Bioscience position as of Q1 2021 after selling out during the quarter.
  • Lebenthal Global Advisors sold 934 Niagen Bioscience shares in Q1 2021, an estimated $4K.
  • Lebenthal Global Advisors first reported a position in Niagen Bioscience in Q4 2020 and held it in 1 quarter.
  • Lebenthal Global Advisors's Niagen Bioscience position peaked at $4K in Q4 2020.
  • 96 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2021.

Based on Lebenthal Global Advisors's 13F filing for Q1 2021, filed 7 May 2021.